SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
202.60    2.60 (1.30%)
Bid:
203.20
Ask:
203.60
Spread: 0.40 (0.197%)
Market Cap: £3.96b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

CEO and CFO appointments

6 Nov 2025 07:00

RNS Number : 3877G
Convatec Group PLC
06 November 2025
 

 

 

Chief Executive Officer and Chief Financial Officer appointments

 

 

London, UK, 6 November 2025 - The Board of Directors of Convatec is pleased to announce the appointments of Jonny Mason as Chief Executive Officer and Fiona Ryder as Chief Financial Officer, with immediate effect.

 

Dr John McAdam, Chair of the Board of Directors, said:

"Since joining the business in 2022 as CFO, Jonny has demonstrated exceptional leadership and is highly regarded for his contribution to Convatec's successful turnaround. Jonny has extensive experience leading publicly listed and international businesses. The Board is confident in his ability to build on the successful transformation led by Karim over the last 6 years, and enable Convatec to deliver its full potential.

 

Fiona's appointment demonstrates the strength of internal talent that Convatec has built. She is a seasoned finance leader with a strong track record in global businesses, having led finance functions while based in the UK, US and Singapore. She has played a pivotal role in delivering Convatec's focus on simplification and productivity, has been fundamental to the success of the FISBE strategy.

 

I look forward to working with Jonny and Fiona to deliver value for all our stakeholders, making a real difference to the lives of people relying on Convatec's products, services and solutions."

 

Jonny Mason, Chief Executive Officer, said:

"Convatec is a brilliant business, full of talented colleagues, making a real difference to the lives of millions of people around the world. As we accelerate our growth and scale up the richest innovation pipeline in Convatec's history, we have significant potential ahead of us. Above all else, we will remain focused on delivering our vision, pioneering trusted medical solutions to improve the lives we touch. As my close colleague and friend Karim often said, Convatec's best days are ahead of us, and I'm determined to prove that he was right."

 

Fiona Ryder, Chief Financial Officer, said:

"I am very pleased for the opportunity to continue to build on what we have achieved through Convatec's turnaround and to support our teams to realise Convatec's full potential. The opportunities ahead of us are substantial. I'm looking forward to continuing to work with Jonny and the team to deliver our plans for the benefit of all our stakeholders."

 

Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025. Fiona Ryder joined Convatec on 3 January 2022 as Group Financial Controller and became Interim CFO on 4 August 2025. Fiona will become a Director of the Company from 6 November 2025.

 

Notes

There is no other information to be disclosed under UK Listing Rule 6.4.8 R in relation to the appointment of Fiona Ryder. 

 

Jonny Mason and Fiona Ryder will be paid in accordance with the Company's Directors' Remuneration Policy. Full details of Jonny Mason's and Fiona Ryder's remuneration arrangements will be disclosed in the Directors' Remuneration Report for 2025.

 

Contacts

Media: mediarelations@convatec.com

Analysts & investors: ir@convatec.com 

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKPBNFBDDBDK
Date   Source Headline
13th Sep 202212:08 pmEQSConvatec Group PLC: Scrip Dividend – Calculation Price
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
4th Aug 20227:00 amRNSInterim Results
7th Jul 202211:53 amRNSDirector Declaration
28th Jun 20225:26 pmRNSBlock listing Interim Review
31st May 20222:00 pmRNSTotal Voting Rights
19th May 202210:00 amRNSDirector/PDMR Shareholding
12th May 20224:25 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update
4th May 20223:31 pmRNSScrip Dividend - Total Issued Shares
3rd May 20227:00 amRNSNotice of Forthcoming Scheduled IR Events
7th Apr 20223:45 pmRNSScrip Dividend – Calculation Price
1st Apr 20224:00 pmRNSHolding(s) in Company
31st Mar 20223:45 pmRNSTotal Voting Rights
30th Mar 202212:00 pmRNSAnnual Report and Accounts 2021 and Notice of AGM
25th Mar 20222:00 pmRNSDirector/PDMR Shareholding
23rd Mar 202211:30 amRNSDirector/PDMR Shareholding
17th Mar 20222:40 pmRNSDirector/PDMR Shareholding
17th Mar 20222:20 pmRNSBoard Change
14th Mar 20227:00 amRNSAcquisition Completion of Triad Life Sciences Inc
8th Mar 20227:00 amRNSAnnual Results
28th Feb 202211:00 amRNSNon-Executive Director Changes
10th Feb 20223:15 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSAcquisition: entry into attractive wound biologics
27th Jan 202211:00 amRNSBoard Committee Changes
20th Dec 20218:45 amRNSBlock Listing Application
16th Dec 20212:00 pmRNSNon-Executive Director appointment
9th Dec 20217:00 amRNSChief Financial Officer succession
1st Nov 20213:35 pmRNSTotal Voting Rights
29th Oct 20217:00 amRNSQ3 Trading Update
18th Oct 20214:30 pmRNSDirector/PDMR Shareholding
1st Oct 20217:00 amRNSPricing of $500M 3.875% Senior Notes due 2029
30th Sep 20211:13 pmRNSConvaTec Announces Offer of $500M Senior Notes
28th Sep 20213:15 pmRNSScrip Dividend - Total Issued Shares
9th Sep 20213:00 pmRNSScrip Dividend - Calculation Price
30th Jul 20213:45 pmRNSDirector/PDMR Shareholding
30th Jul 20217:00 amRNSInterim Results
28th Jun 202112:40 pmRNSDirector Declaration
1st Jun 202111:45 amRNSTotal Voting Rights
17th May 20213:15 pmRNSDirector/PDMR Shareholding
7th May 20212:50 pmRNSResult of AGM
29th Apr 20217:00 amRNSQ1 Trading Update
28th Apr 202112:45 pmRNSScrip Dividend - Total Issued Shares
12th Apr 20213:15 pmRNSScrip Dividend - Calculation Price
22nd Mar 20213:40 pmRNSAnnual Report and Accounts 2020 and Notice of AGM
11th Mar 20213:50 pmRNSDirector/PDMR Shareholding
5th Mar 20217:00 amRNSAnnual Results
22nd Feb 202111:30 amRNSDirector Declaration
21st Dec 202011:00 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.